Dr. Shiladitya Sengupta is an associate professor of medicine and HST at Harvard Medical School and leads the center for engineered therapeutics at the Mass General-Brigham Hospital. His laboratory use tools from nanotechnology and bioengineering to explore biological phenomenon at distinct scales, and to design new therapeutics. For example, he developed the first layer-by-layer nanoparticle that allows targeting different components of a tumor on a temporal scale (Nature). Recently, his lab discovered a new mechanism of tumor immune evasion, where the cancer cells harvest immune cell mitochondria (Nature Nanotechnology). Many of his inventions/research have led to start-ups (he cofounded Cerulean Pharma, Vyome Therapeutics, Farcast Biosciences, Allysum Therapeutics, which have raised over $300M in R&D funding), or been commercialized (Nimulid™, CANScript™, MRT-technology in Anaboom™, VT1953 in Phase 3 trials, AT1965 entering Phase 1 trials). Over 100 students and postdoctoral fellows have trained in his laboratory, have won multiple awards and fellowships, and have gone on to successful careers in academia and in the biotech industry. He has received the TR35 Top 35 Global Innovators award from MIT Technology Review magazine, the Era of Hope scholar award from US Department of Defense, etc. He completed his undergraduate education at the All India Institute of Medical Sciences, New Delhi, his PhD in Pharmacology as a Nehru and Chevening scholar from Trinity College, Cambridge University, and his fellowship in biological engineering at Massachusetts Institute of Technology, before joining Harvard as faculty.